

## Viral MRI Contrast Agents: Coordination of Gd by Native Virions and Attachment of Gd Complexes by Azide-Alkyne Cycloaddition

Duane E. Prasuhn Jr.,<sup>‡</sup> Robert Yeh,<sup>‡</sup> Andre Obenaus,<sup>†</sup> Marianne Manchester,<sup>§</sup> M. G. Finn<sup>‡\*</sup>

Departments of Chemistry<sup>‡</sup> and Cell Biology,<sup>§</sup> The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037

<sup>†</sup>Non Invasive Imaging laboratory, Loma Linda University, Loma Linda, CA 92354

### Electronic Supplementary Information (ESI)


#### *Materials and Instrumentation*

Kits for Modified Lowry Protein Assay were purchased from Pierce. pQE-60 and M15 cells were purchased from Qiagen, while IPTG (dioxane-free, high purity) was obtained from Calbiochem. Metal standards for inductively coupled plasma optical emission spectrometry (ICP-OES) were purchased from Inorganic Ventures, Inc. All other chemicals were purchased from Acros Organics or Sigma-Aldrich and used as received. <sup>1</sup>H NMR spectra were measured at 200 MHz on a Varian Mercury 200 instrument. Mass spectra were taken using a HP 110 LC/MS spectrometer (model G1946A). UV-visible measurements were performed on a HP 845x UV-visible spectrophotometer. (ICP-OES) measurements were taken on a Varian VISTA AX CCD simultaneous spectrometer equipped with a Teflon nebulizer and sample uptake tubing. All standards and samples were spiked with an internal standard of yttrium at a final concentration of 10 ppm. FPLC analyses were performed with AKTA Explorer (Amersham Pharmacia Biotech) equipment, using Supersose-6™ size-exclusion columns. Ultracentrifugation was performed with a Beckman Optima L-90K Ultracentrifuge equipped with either SW41 or 50.2 Ti rotors. Magnetic resonance data were collected on a Bruker Avance 11.7T MRI (Bruker Biospin, Billerica MA), a Bruker Avance 4.7T (200 MHz) MRI, and a 1.5T (64 MHz) MRI imager (Magnetom SP400, Siemens Medical Systems, Erlangen, Germany).

#### *Propagation and Isolation of Virus Particles*

CPMV particles were produced in cowpea plants and isolated using previously published procedures.<sup>1</sup> The K16M Q $\beta$  coat protein gene was cloned into the vector pQE-60 and expressed under IPTG control in M15 cells. After expression, collected cells were lysed by sonication and lysozyme treatment and then centrifuged to remove insoluble cell components. Virus was precipitated from the resulting supernatant using 8% PEG 8000. Following further centrifugation, the isolated pellet was resuspended in 0.1M potassium phosphate pH 7.0. Virus was then purified by ultracentrifugation through 10-40% sucrose gradients. A more detailed procedure for expression and isolation of Q $\beta$  particles will be presented elsewhere, and may be obtained from the author. Note that we find that gradient ultracentrifugation purification is more reliable than size-exclusion “spin columns” previously employed (and still used for preliminary cleanup in some cases). CPMV concentrations were determined by absorbance at 260 nm (0.1 mg/mL virus sample gives an absorbance of 0.8). Q $\beta$  concentrations were determined using the Modified Lowry Protein Assay.<sup>2</sup>

**Figure S1.** Synthetic manipulations.



Synthesis of Gd(DOTA) alkyne complex 4 (Figure S1)

*N*-Propargylbromoacetamide (**7**). Aqueous NaOH (0.1 M, 40 mL) was layered on top of a solution of propargylamine (4.0 mL, 58.3 mmol) in 200 mL CH<sub>2</sub>Cl<sub>2</sub>. Bromoacetyl bromide (16.3 mL, 187 mmol) was carefully added by syringe into the CH<sub>2</sub>Cl<sub>2</sub> layer, causing the immediate formation of a white precipitate. The reaction was then stirred vigorously for 2.5 hours at room temperature, during which time the precipitate redissolved. The reaction solution was transferred to a separatory funnel with excess CH<sub>2</sub>Cl<sub>2</sub> and water. The aqueous layer was isolated and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 100 mL). All organic fractions were combined and washed with 50 mM Na<sub>2</sub>CO<sub>3</sub> (3 x 100 mL). The resulting solution was dried over MgSO<sub>4</sub> and reduced to dryness by rotary evaporation, yielding a brown oil. Storage overnight under vacuum at room temperature produced a tan solid (3.6 g, 35%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): δ 6.76 (br, 1H, NH), 4.09 (dd, 2H, NHCH<sub>2</sub>), 3.90 (s, 2H, CH<sub>2</sub>), 2.29 (t, 1H, C-H); ESI-MS (9:1 CH<sub>3</sub>CN/H<sub>2</sub>O w/ 0.1% TFA) 176 (M+H<sup>+</sup>, 100%), 198 (M+Na<sup>+</sup>, 62)

*Compound 6*. In a 500 mL flask, cyclen **5** (4.09 g, 23.7 mmol), NaHCO<sub>3</sub> (6.22 g, 74.0 mmol), and *t*-butylbromoacetate (10.5 mL, 71.1 mmol) were dissolved in 400 mL CH<sub>3</sub>CN (HPLC grade). The mixture was stirred at room temperature for 48 hours and then filtered through a frit and the trapped solids were washed with CH<sub>3</sub>CN (15 mL). The filtrate was evaporated to dryness and the residual solid was broken up with a spatula and then treated with excess diethyl

ether (400 mL). An insoluble white solid was isolated by filtration, and was washed with copious amounts of diethyl ether (100mL). Drying in a vacuum oven at 55°C gave a yield of 7.5 g (54%).<sup>3</sup> <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz) δ 10.0 (br, 2H, NH<sub>2</sub>), 3.39 (s, 4H, CH<sub>2</sub>), 3.30 (s, 2H, CH<sub>2</sub>), 3.11 (s, 4H, CH<sub>2</sub>), 2.92 (s, 12H, CH<sub>2</sub>), 1.48 (s, 27H, C(CH<sub>3</sub>)<sub>3</sub>); ESI-MS (9:1 CH<sub>3</sub>CN/H<sub>2</sub>O w/ 0.1% TFA) *m/z* 516 (M+H<sup>+</sup>, 100%), 538 (M+Na<sup>+</sup>, 10)

**Compound 8.** Compound **6** (1.48 g, 2.48 mmol), **7** (1.29 g, 7.33 mmol), and K<sub>2</sub>CO<sub>3</sub> (2.78 g, 20.1 mmol) were placed in a 500 mL flask and the mixture was then dissolved in CH<sub>3</sub>CN (HPLC grade, 150 mL). The reaction mixture was heated at reflux for 48 hours, cooled to room temperature, and the solvent was removed by rotary evaporation. CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added, the mixture was filtered through filter paper, and then evaporated to dryness, yielding crude **8** as a golden oil, which was taken on to the next step without purification. ESI-MS (9:1 CH<sub>3</sub>CN/H<sub>2</sub>O w/ 0.1% TFA) 610 (M+H<sup>+</sup>, 100%), 632 (M+Na<sup>+</sup>, 90).

**Compound 9.** Compound **8** was dissolved in 30 mL of 1:1 CH<sub>2</sub>Cl<sub>2</sub>/TFA and stirred overnight. Solvent was removed by rotary evaporation and the resulting oil was resuspended in MeOH (20 mL) and again evaporated to dryness. This cycle was repeated twice more, and then three times with CH<sub>2</sub>Cl<sub>2</sub>. The crude oil was redissolved in a minimal volume of MeOH and then treated with excess diethyl ether, yielding crude **9** as a hygroscopic tan solid (1.38 g).<sup>4</sup> ESI-MS (9:1 CH<sub>3</sub>CN/H<sub>2</sub>O w/ 0.1% TFA) 442 (M+H<sup>+</sup>, 100%), 221.5 (M+2H<sup>+</sup>, 85).

**Gd complex 4.** Ligand **9** (0.97 g, 2.2 mmol) and Gd<sub>2</sub>O<sub>3</sub> (478mg, 1.32 mmol) were heated in 25 mL H<sub>2</sub>O at reflux overnight. The mixture was cooled to room temperature and filtered through a layer of Celite and sand. The water was removed by rotary evaporation and the resulting oil was dissolved in a minimal volume of MeOH. Addition of excess diethyl ether produced an off-white solid (722 mg, 1.21 mmol).<sup>5</sup> ESI-MS (9:1 CH<sub>3</sub>CN/H<sub>2</sub>O w/ 0.1% TFA) 597(M+H<sup>+</sup>, 100%), 299 (M+2H<sup>+</sup>, 85).

#### Bioconjugation to CPMV and Qβ (particles 2b and 3b).

The *N*-acylated azide particles **2a** and **3a** were prepared by reaction of CPMV and Qβ with *N*-hydroxysuccinimide ester **1**<sup>6</sup> by previously published procedures.<sup>7</sup> These virus particles decorated with terminal azides were then subjected to the CuAAC process,<sup>6</sup> as follows. Under a nitrogen atmosphere in an inert-atmosphere glove box, **2a** (final concentration of 2 mg/mL, 21.4 μM in protein subunits) and **4** (1 mM) were dissolved in degassed 0.1M Tris buffer, pH 8.0. A 100 mM stock of Cu(CH<sub>3</sub>CN)<sub>4</sub>OTf was prepared in degassed CH<sub>3</sub>CN and a 100 mM stock of sulfonated bathophenanthroline ligand in degassed 0.1M Tris buffer, pH 8.0. A 1:2 mixture of Cu(CH<sub>3</sub>CN)<sub>4</sub>OTf and ligand was prepared and added to achieve a final concentration of 1 mM Cu<sup>+</sup> and 2 mM ligand. For the Qβ variation, the reagents used were **3a** (2 mg/mL, 140 μM in protein subunit), **4** (2.9 mM), Cu(CH<sub>3</sub>CN)<sub>4</sub>PF<sub>6</sub> (715 μM), and bathophenanthroline ligand (1.4 mM). The reactions were sealed, brought out of the glove box, and agitated gently on a rotisserie mixer overnight. Each reaction was conducted on 1 mL of total solution in 2 mL eppendorf tubes; larger-scale reactions were performed by multiplying the number of these tubes, rather than by using larger reaction volumes. After reacting overnight, individual reactions were combined and the virus particles were purified on 10-40% sucrose gradients followed by ultracentrifugation, with a second gradient/ultracentrifugation step if required to completely remove all of the excess small molecules. The number of attached complexes per virion was calculated by







